We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed ...
EyePoint Pharmaceuticals, Inc. is a specialty b...
With 40 million infertile people worldwide, MedAnswers connects patients with mult...
With 40 million infertile people worldwide, Med...
Aeglea a clinical-stage biotechnology company that engineers next generation human...
Aeglea a clinical-stage biotechnology company t...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
Together, a potent new drug and a blood test to guide its use can be a life change...
Together, a potent new drug and a blood test to...
An emerging leader in the specialty pharmaceuticals industry, ANI Pharmaceuticals ...
An emerging leader in the specialty pharmaceuti...
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
Join the National Investor Network and get the latest information with your interests in mind.